HQK-1004

· HemaQuest Pharmaceuticals Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HQK-1004, covering 2011-08-01 to 2011-08-01. Get the full timeline:

Most recent: Clinical Trial Update: Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders [Phase 2]

See pricing